Biopharmaceuticals

Viking's small extension study of weight-loss drug shows sustained weight loss; shares surge intraday

Viking says its obesity injection continued to produce weight loss in a small extension study, with some patients retaining most of the effect after dosing frequency was reduced; shares were up as much as intraday 36.6%。